GoAI
Get started
NovaBridge Biosciences logo

NovaBridge Biosciences

NBP

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.00

+$0.09 · +4.71%

Aug 21, 4:00 PM ET

Pre-market

$1.99

−$0.01 · -0.50%

Aug 24, 4:01 AM ET

NBP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

30

Weakening

Sentiment

44

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Srishti Gupta
Listed since
Jan 17, 2020
Employees
30

Market position

Day range

Current $2.00

52-week range

Current $2.00

Open
$1.90
Previous close
$1.91
Volume
443.08K
0.62× average
Average volume
711.38K
Average daily volume
Market cap
230.53M USD
Beta
1.48
Market reference 1
50-day average
$1.7706
+12.96% above average
200-day average
$2.8172
-29.01% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
136.04M USD
EV / EBITDA
-10.19×
Earnings yield
-3.99%
Free cash flow yield
-12.43%

Profitability & efficiency

Return on equity
-20.03%
Return on assets
-17.76%
Return on invested capital
-40.20%

Financial health

Current ratio
8.09×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends13216%-3471%-20158%-36846%Gross margin, FY2021: 47.25%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Operating margin, FY2021: -2353.06%Operating margin, FY2022: 3422.17%Operating margin, FY2023: -11395.09%Net margin, FY2021: -2648.70%Net margin, FY2022: 9044.58%Net margin, FY2023: -32674.02%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.25%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Operating margin FY2021 -2353.06%. Operating margin FY2022 3422.17%. Operating margin FY2023 -11395.09%. Net margin FY2021 -2648.70%. Net margin FY2022 9044.58%. Net margin FY2023 -32674.02%.

Income trends

Revenue

4.49M USD+15.18M USD

Operating income

−13.48M USD+96.41%

Net income

−6.61M USD+95.92%
Income trends across reported periods329.98M USD−637.84M USD−1.61B USD−2.57B USDRevenue, FY2021: 88.03M USDRevenue, FY2022: −10.7M USDRevenue, FY2023: 4.49M USDOperating income, FY2021: −2.07B USDOperating income, FY2022: −366.08M USDOperating income, FY2023: −511.16M USDOperating income, FY2024: −375.36M USDOperating income, FY2025: −13.48M USDNet income, FY2021: −2.33B USDNet income, FY2022: −967.52M USDNet income, FY2023: −1.47B USDNet income, FY2024: −162.26M USDNet income, FY2025: −6.61M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 88.03M USD. Revenue FY2022 −10.7M USD. Revenue FY2023 4.49M USD. Operating income FY2021 −2.07B USD. Operating income FY2022 −366.08M USD. Operating income FY2023 −511.16M USD. Operating income FY2024 −375.36M USD. Operating income FY2025 −13.48M USD. Net income FY2021 −2.33B USD. Net income FY2022 −967.52M USD. Net income FY2023 −1.47B USD. Net income FY2024 −162.26M USD. Net income FY2025 −6.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——4.49M USD−10.7M USD88.03M USD
Cost of goods sold————46.43M USD
Gross profit——4.49M USD−10.7M USD41.59M USD
Research and development8.99M USD158.9M USD114.36M USD155.51M USD190.29M USD
Selling, general, and administrative4.48M USD216.46M USD63.91M USD199.88M USD899.94M USD
Operating expenses13.48M USD375.36M USD515.65M USD355.38M USD2.11B USD
Interest income1.09M USD54.64M USD7.3M USD4.95M USD21.33M USD
Interest expense——101.85K USD——
Depreciation and amortization122.37K USD1.91M USD3.37M USD9.7M USD13.78M USD
Operating income−13.48M USD−375.36M USD−511.16M USD−366.08M USD−2.07B USD
Net income−6.61M USD−162.26M USD−1.47B USD−967.52M USD−2.33B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
56%
5 beats, 3 misses, 1 met estimate
Average EPS surprise
-279.88%
9 comparable reports
Latest EPS result
-0.22
Estimate -0.01 · Miss by 2660.35%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-0.19-0.37-0.55Q3 '24BeatQ4 '24MissQ1 '25MetQ2 '25BeatQ3 '25BeatQ4 '25BeatQ3 '26MissQ4 '26Estimate
Q3 2024, reported Aug 28, 2024: actual -0.07, estimate -0.51, surprise +86.27%, Beat. Q4 2024, reported Nov 14, 2024: actual -0.25, estimate -0.16, surprise -56.25%, Miss. Q1 2025, reported Mar 31, 2025: actual -0.06, estimate -0.06, surprise 0.00%, Met estimate. Q2 2025, reported May 15, 2025: actual -0.02, estimate -0.063, surprise +68.42%, Beat. Q3 2025, reported Aug 26, 2025: actual -0.025, estimate -0.06, surprise +58.33%, Beat. Q4 2025, reported Dec 18, 2025: actual -0.025, estimate -0.06, surprise +58.33%, Beat. Q3 2026, reported Jul 30, 2026: actual -0.22, estimate -0.008, surprise -2660.35%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates50.17M33.78M17.39M1MQ2 '23No estimateQ3 '23MissQ1 '24MissQ3 '24BeatQ4 '24EstimateQ1 '25Estimate
Q2 2023, reported Apr 4, 2023: actual 46.55M USD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 17, 2023: actual 2.7M USD, estimate 7M USD, surprise -61.43%, Miss. Q1 2024, reported Mar 14, 2024: actual 1.18M USD, estimate 7M USD, surprise -83.11%, Miss. Q3 2024, reported Aug 28, 2024: actual 9.86M USD, estimate 1.5M USD, surprise +557.17%, Beat. Q4 2024, reported Nov 14, 2024: actual —, estimate 1.5M USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual —, estimate 1.5M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$9.00

350.00% upside
Past 12 months12-month forecastHigh $9.00Average $9.00Low $9.00

Rating distribution

11 ratings
Strong buy00%
Buy11100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
Cantor FitzgeraldmaintainOverweight

NBP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding NBP

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Emerging Markets ETF logoState Street SPDR Portfolio Emerging Markets ETFSPEM
Market value
569K
Weight
0.00%
AUM
17.57B USD
Expense ratio
0.07%
Price / 1D
$52.38+0.61%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
271.74K
Weight
0.11%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
88.41K
Weight
0.01%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%
State Street SPDR S&P China ETF logoState Street SPDR S&P China ETFGXC
Market value
28.15K
Weight
0.01%
AUM
474.65M USD
Expense ratio
0.59%
Price / 1D
$91.50+0.51%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
7.67K
Weight
0.01%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%

Continue in GoAI

Research NBP

research.disclaimer